Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 5,776 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Clear all
Completed Phase 3 Interventional Results available

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

NCT00098059
View directory record Official record
Conditions
Herpes Simplex
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 12 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

PK/PD Pediatric ADHD Classroom Study

NCT02536105
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of an Interdisciplinary Decision Guide for Infant Feeding Assessment

NCT04850794
View directory record Official record
Conditions
Premature Birth, Feeding and Eating Disorders of Childhood
Interventions
Decision Support Tool
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 27, 2026, 9:50 AM EDT
Recruiting Phase 4 Interventional

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT07524946
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes

NCT01323088
View directory record Official record
Conditions
Abdominal Obesity, Physical Activity
Interventions
Control, Resistance Exercise, Aerobic exercise
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 27, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

NCT02624388
View directory record Official record
Conditions
Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor, Neuroblastoma, Ewing Sarcoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Medulloblastoma, Germ Cell Tumor, Wilms Tumor, Brain Neoplasms, Medulloblastoma, Childhood, Neuroectodermal Tumors, Primitive
Interventions
Genistein, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer

NCT01670461
View directory record Official record
Conditions
Cancer
Interventions
FACE, Standard of Care (SOC) Control
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
14 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 27, 2026, 9:50 AM EDT
Recruiting Phase 2 Interventional

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588
View directory record Official record
Conditions
PIK3CA-related Overgrowth Spectrum (PROS)
Interventions
Alpelisib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 27, 2026, 9:50 AM EDT
Terminated Not applicable Interventional Results available

Unsweetened Sparkling Water and Changes in Sweetness Perception in Adolescents

NCT05966870
View directory record Official record
Conditions
Obesity, Adolescent, PreDiabetes
Interventions
Unsweetened flavored sparkling water
Other
Lead sponsor
Indiana University
Other
Eligibility
10 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

NCT00441896
View directory record Official record
Conditions
Infantile Spasms
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
4 Months to 24 Months
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 27, 2026, 9:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
172
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiation Therapy for Pediatric Sarcomas

NCT01763970
View directory record Official record
Conditions
Sarcoma, Metastatic Disease, Bony Sites
Interventions
SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Stanford, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Communication and Support in the Pediatric Intensive Care Unit

NCT02144779
View directory record Official record
Conditions
Reducing Post Traumatic Stress
Interventions
Assigned to palliative care team, Usual Care
Behavioral
Lead sponsor
Ross Hays
Other
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 27, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

NCT01032070
View directory record Official record
Conditions
Recurrent or Refractory Pediatric Ependymoma
Interventions
erlotinib, etoposide
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
1 Year to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

NCT00240994
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 27, 2026, 9:50 AM EDT
Recruiting Phase 3 Interventional

Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution

NCT04792034
View directory record Official record
Conditions
ENT Disorder, Nasal Procedures, Nasal Anesthesia, Nasal Mucosa Surgery
Interventions
Cocaine Hydrochloride Nasal Solution
Drug
Lead sponsor
LXO Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Columbia, South Carolina • Lugoff, South Carolina • Newberry, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 9:50 AM EDT
Withdrawn Phase 1 Interventional

Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

NCT03888534
View directory record Official record
Conditions
Precursor Cell Lymphoblastic Leukemia-lymphoma
Interventions
Ixazomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Jackson, Mississippi • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 27, 2026, 9:50 AM EDT
Active, not recruiting Phase 4 Interventional

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

NCT03987763
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Fountain Valley, California • Thousand Oaks, California • Doral, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 9:50 AM EDT
Completed No phase listed Observational

Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes

NCT01987921
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 25 Years
Enrollment
5,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

NCT00095121
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Latino Fathers Promoting Healthy Youth Behaviors

NCT03469752
View directory record Official record
Conditions
Diet Modification, Physical Activity, Parenting, Adolescent Obesity
Interventions
Parent education classes
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 14 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 27, 2026, 9:50 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

QPlus Pediatric Reference Interval

NCT05645133
View directory record Official record
Conditions
Pediatric ALL, Healthy
Interventions
Diagnostic Test
Device
Lead sponsor
HemoSonics LLC
Industry
Eligibility
Up to 17 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 27, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Waterproof Casting for Pediatric Distal Radius Fractures

NCT02095106
View directory record Official record
Conditions
Pediatric Distal Radius Fractures
Interventions
Waterproof Cast, Traditional cast
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 27, 2026, 9:50 AM EDT